Plasma cell myeloma
Not yet recruitingA study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies
A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies
- Disease:Plasma cell myeloma
- Substances:Belantamab MafodotinMezigdomide
France- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Centre Hospitalier Universitaire De Saint Etienne






